Sheahan Anjali V, Biankin Andrew V, Parish Christopher R, Khachigian Levon M
Department of Pathology, Dana-Farber Cancer Institute, Boston 02115, MA, United States of America.
Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow G61 1QH, Scotland, United Kingdom.
Oncotarget. 2018 Apr 20;9(30):21613-21627. doi: 10.18632/oncotarget.25085.
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.
胰腺癌的预后很差，尤其是对于那些出现不可切除肿瘤的患者。我们对2014年至2016年间针对出现不可切除（局部晚期或转移性）肿瘤的患者进行的胰腺癌临床试验进行了文献计量分析。我们讨论了一系列采用FOLFIRINOX、吉西他滨+纳米白蛋白结合型紫杉醇联合方案的研究以及使用分子靶向治疗的研究。主要关注领域包括表皮生长因子受体（EGFR）和血管内皮生长因子受体（VEGFR）的双重靶向、免疫治疗或多模式方法——将化疗与放疗相结合。我们还指出了对低流行亚型进行分子选择的必要性。从这些关键试验中获得的关键见解应能改善这种毁灭性癌症的临床结局。
